Video

Expert Discusses the Evolving Field of Gynecologic Cancers

The field of ovarian cancer is changing rapidly, and moving toward an era of precision medicine.

It’s an exciting time for gynecologic malignancies, as treatment options continue to be explored, said Maurie Markman, M.D., resident of Medicine and Science, Cancer Treatment Centers of America.

Three PARP inhibitors are now approved for the treatment of ovarian cancer — Zejula (niraparib), Lynparza (olaparib) and Rubraca (rucaparib) – in the maintenance setting. Now, checkpoint inhibitors, a type of immunotherapy agent, are the next to be explored, according to Markman. An increase in molecular testing will continue to move the field into an era of precision medicine, where each patient will have a specific treatment plan that is tailored to their disease.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Daniel Jernazian, who beat cancer twice, credits his sports mindset for survival and calls it winning his ‘life World Championship’.
Patients in rural or underserved areas may have worse outcomes, highlighting the need for early support to address care access barriers.
Image of man with text.
Dr. Emre Yekedüz discusses how ASCO 2025 highlights precision medicine, biomarkers and the gut microbiome as keys to advancing kidney cancer care.
Dr. Breelyn Wilky stresses the importance of expert guidance and second opinions for patients with GIST, as treatment options continue to evolve rapidly.
Mark Daniels, 83, credits CAR T-cell therapy and compassionate care for helping him overcome lymphoma and endure the isolating treatment toll.
An early study of BGB-16673 for hard-to-treat leukemia found that side effects were manageable with no new safety concerns.
Image of woman with text.
Image of goy, and text.
Watch oncology dietitian Kenisha Parikh prepare creamy lentil soup, a soothing, protein-packed recipe to help ease side effects during treatment.
Related Content